Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cantor Fitzgerald Downgrades DICE Therapeutics to Neutral, Lowers Price Target to $48

Author: Benzinga Newsdesk | June 20, 2023 12:44pm
Cantor Fitzgerald analyst Prakhar Agrawal downgrades DICE Therapeutics (NASDAQ:DICE) from Overweight to Neutral and lowers the price target from $58 to $48.

Posted In: DICE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist